AIkido Pharma Inc. (AIKI)

AIkido Pharma Inc. (AIKI) — VMCI valuation read

AIkido Pharma Inc. (AIKI) carries a VMCI composite of 52/100, 2 points above the Healthcare sector median of 50. Among mid-cap names, that gap places AIKI in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The AIKI insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads AIKI trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 0.1x leaves covenant headroom, the line to track on AIkido Pharma Inc.'s next 10-Q.

AIKI fell 1.6% over the trailing 7 days, with a -13.6% read on a 30-day basis.